Co-Diagnostics
CODX

$1.12

1.82%

Market Cap: 35.7M

About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Employees: 155

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

145% more call options, than puts

Call options by funds: $108K | Put options by funds: $44K

1.38% less ownership

Funds ownership: 15.33% [Q4 2023] → 13.95% (-1.38%) [Q1 2024]

17% less funds holding

Funds holding: 47 [Q4 2023] → 39 (-8) [Q1 2024]

22% less capital invested

Capital invested by funds: $6.25M [Q4 2023] → $4.89M (-$1.36M) [Q1 2024]

57% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 14

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$2

79%

upside

Avg. target

$2.17

93%

upside

High target

$2.50

123%

upside

3 analyst ratings

0 positive

0%

3 neutral

100%

0 negative

0%

HC Wainwright & Co. Yi Chen	79%upside $2	Neutral Reiterated	17 Jun 2024
HC Wainwright & Co. Yi Chen	79%upside $2	Neutral Maintained	13 May 2024
HC Wainwright & Co. Yi Chen	123%upside $2.5	Neutral Maintained	15 Mar 2024

See Analyst Rankings

Financial journalist opinion

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States

SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week. Co-Dx vector control technology includes Vector Smart® PCR tests used in environmental (non-diagnostic) surveillance of mosquito pools for mosquito-borne illnesses like West Nile virus, Zika, dengue and chikungunya.

Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21. FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relationships, and for strengthening business ties with the global medical device and equipment market, with exhibitors from 116 countries and more than 15,000 expected professional attendees.

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY , June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use. Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received.

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript

Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results

SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: Revenue of $0.5 million, down from $0.6 million during the prior year.

Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results

Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast

SALT LAKE CITY , April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan

SALT LAKE CITY , April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference (APRC) of the International Union Against Tuberculosis and Lung Disease on April 26-29, 2024 in Taipei, Taiwan. The theme for the 2024 conference is "Shaping a Safer World Through High-Quality Holistic Healthcare," reflecting the organizers' vision to discuss current evidence, share ideas and information, and accelerate innovation.

Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan

Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event

Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY , April 12, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it held the ribbon cutting event for its new manufacturing facility yesterday in the City of South Salt Lake. The facility has been designed to manufacture the Co-Dx Pro™ instrument and test cups for the new platform*, as well as the Company's patented Co-Primers™ chemistry that underpins the Company's PCR diagnostic tests.

Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event

Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

SALT LAKE CITY , April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Company, Richard Abbott (President) served as the President of Advanced Conceptions, Inc., a wholly-owned subsidiary of Co-Diagnostics since December 2021, and has been instrumental in establishing the teams and technology of the Co-Dx PCR platform*.

Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

See News Rankings